Proteomic profiling of mature CD10+ B-cell lymphomas.

Proteomic profiling with protein-chip technology has been used successfully to discover biomarkers with potential clinical usefulness in several cancer types. Little proteomic study has been done in B-cell lymphomas. We determined whether the expression of a set of proteins by protein-chip technology coupled with new informatics tools could be used to build a model to molecularly classify B-cell lymphoma subgroups. We used surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to analyze 18 CD10+ B-cell lymphomas, including 6 grade 1 (G1) follicular lymphomas (FLs), 7 grade 3 (G3) FLs, and 5 Burkitt lymphomas. We used 7 reactive follicular hyperplasia cases as a control group. By using SAX2 ProteinChip arrays (Ciphergen Biosystems, Fremont, CA), we found a unique protein expression profile for each type of lesion. Two-way hierarchical clustering analysis of these protein expression profiles differentiated reactive follicular hyperplasia, FL, and Burkitt lymphoma, with 5 major clusters of differentially expressed protein peaks. In addition, we identified histone H4 as a potential differentially expressed protein marker that seems to distinguish G1 from G3 FL. To our knowledge, this is the first proteomic study using protein-chip technology for molecular classification of B-cell lymphoma subtypes with clinical samples.

[1]  X. Xiao,et al.  Development of Proteomic Patterns for Detecting Lung Cancer , 2004, Disease markers.

[2]  J. Richie,et al.  Prostate carcinoma tissue proteomics for biomarker discovery , 2003, Cancer.

[3]  T. Yip,et al.  Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. , 2003, Clinical chemistry.

[4]  George L. Wright,et al.  SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. , 2002, Expert review of molecular diagnostics.

[5]  H. Ohno,et al.  Characterization of t(3;6)(q27;p21) breakpoints in B-cell non-Hodgkin's lymphoma and construction of the histone H4/BCL6 fusion gene, leading to altered expression of Bcl-6. , 2002, Cancer research.

[6]  George L. Wright Jr,et al.  SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis , 2002 .

[7]  Takeshi Inoue,et al.  Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. , 2002, Biochemical pharmacology.

[8]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[9]  E. Petricoin,et al.  Clinical potential of proteomics in the diagnosis of ovarian cancer , 2002, Expert review of molecular diagnostics.

[10]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[11]  L. Liotta,et al.  Proteomic Patterns of Nipple Aspirate Fluids Obtained by SELDI-TOF: Potential for New Biomarkers to Aid in the Diagnosis of Breast Cancer , 2002, Disease markers.

[12]  S. Bates,et al.  Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  W. Chan,et al.  Gene expression analysis in aggressive NHL , 2001, Annals of Hematology.

[14]  G. Wright,et al.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.

[15]  B. Peterson.  Current treatment of follicular low-grade lymphomas. , 1999, Seminars in oncology.

[16]  A. Matolcsy.  High-grade transformation of low-grade non-Hodgkin's lymphomas: mechanisms of tumor progression. , 1999, Leukemia & lymphoma.

[17]  R. Gascoyne,et al.  Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Glass,et al.  The national cancer data base report on non‐hodgkin's lymphoma , 1997, Cancer.

[19]  S. Gallagher.  One‐Dimensional SDS Gel Electrophoresis of Proteins , 1995, Current protocols in molecular biology.

[20]  T. Greiner.  mRNA microarray analysis in lymphoma and leukemia. , 2004, Cancer treatment and research.

[21]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[22]  Nj,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .